ArticleHepatology communications2026
Circulating multi-omic signature of disease severity and cholangiocarcinoma in primary sclerosing cholangitis.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease often associated with inflammatory bowel disease (IBD) that can progress to cirrhosis or cholangiocarcinoma (CCA), both carrying a poor prognosis. The mechanisms driving disease progression remain poorly understood. We aimed to identify circulating multi-omic signatures linked to PSC severity (alkaline phosphatase, bilirubin, fibrosis), IBD, and CCA to elucidate underlying biology and discover potential biomarkers for risk stratification and disease monitoring.
methodsWe quantified 737 proteins, 1083 metabolites, and 4573 miRNAs using plasma from 33 patients with PSC with various clinical presentations. We applied machine learning-driven analysis and network-based modeling for the data integration and analysis of associations. Parameters robustly identified in both methods were considered for tailored pathway enrichment analysis.
resultsWe identified circulating multi-omic profiles associated with PSC disease severity, IBD, and CCA. IBD-specific alterations were subtle; however, we noted associations between microbial-derived metabolites and colorectal cancer-related miRNAs. Severe PSC shared molecular features with PSC-CCA, indicating early activation of malignant pathways in PSC. Severe PSC was characterized by immune-interacting and epithelial-interacting proteins, bile acid and glutathione-related metabolites, and miRNAs regulating fibrosis, inflammation, extracellular matrix remodeling, and cell cycle control, overlapping with PSC-CCA. In established PSC-CCA, we observed coordinated alterations in oncogenic miRNAs, growth factor-related proteins, and depletion of sulfated phenolics and methylxanthines, reflecting extracellular matrix remodeling, inflammatory microenvironment reprogramming, and impaired hepatic detoxification. Overall, pathway enrichment analysis revealed an infection-like and cancer-associated signature defining PSC pathogenesis.
conclusionsCirculating multi-omic profiles capture the key features of PSC severity and associated CCA. These findings provide mechanistic insights and identify potential biomarkers for cancer risk stratification and disease monitoring using PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.